

Fabian Trillsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3286279/publications.pdf>

Version: 2024-02-01

95
papers

1,877
citations

257450

24
h-index

302126

39
g-index

100
all docs

100
docs citations

100
times ranked

2996
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 16923-16935.	1.8	207
2	Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. <i>British Journal of Cancer</i> , 2015, 113, 1358-1366.	6.4	110
3	The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma "Analysis of patient data in the prospective OVCAD study. <i>Gynecologic Oncology</i> , 2013, 131, 15-20.	1.4	99
4	Clinical management of primary vulvar cancer. <i>European Journal of Cancer</i> , 2011, 47, 2315-2321.	2.8	82
5	Clinical management of borderline ovarian tumors. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1115-1124.	2.4	65
6	Value of Tertiary Cytoreductive Surgery in Epithelial Ovarian Cancer: An International Multicenter Evaluation. <i>Annals of Surgical Oncology</i> , 2013, 20, 1348-1354.	1.5	64
7	Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. <i>Annals of Oncology</i> , 2014, 25, 1320-1327.	1.2	59
8	Patterns of distant metastases in vulvar cancer. <i>Gynecologic Oncology</i> , 2016, 142, 427-434.	1.4	47
9	The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018, 151, 61-68.	1.4	44
10	Management of patients with vulvar cancer: a perspective review according to tumour stage. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 183-192.	3.2	43
11	Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. <i>Journal of Ovarian Research</i> , 2013, 6, 42.	3.0	41
12	Clinical management of epithelial ovarian cancer during pregnancy. <i>European Journal of Cancer</i> , 2014, 50, 963-971.	2.8	37
13	Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 924, 3-8.	1.6	37
14	The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node. <i>Annals of Surgical Oncology</i> , 2016, 23, 2508-2514.	1.5	37
15	Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer. <i>Tumor Biology</i> , 2015, 36, 9023-9030.	1.8	36
16	Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9169.	4.1	34
17	Systemic treatment of vulvar cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 629-637.	2.4	33
18	Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study. <i>British Journal of Cancer</i> , 2015, 112, 660-666.	6.4	32

#	ARTICLE	IF	CITATIONS
19	E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2016, 114, 213-220.	6.4	32
20	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7621-7632.	7.0	31
21	Secondary Sentinel Node Biopsy After Previous Excision of the Primary Tumor in Squamous Cell Carcinoma of the Vulva. <i>Annals of Surgical Oncology</i> , 2013, 20, 1701-1706.	1.5	30
22	The prognostic significance of Jun transcription factors in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1673-1680.	2.5	29
23	Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapyâ€“Innovative Models Prolong Survival (OCTIPS) Consortium. <i>European Journal of Cancer</i> , 2017, 79, 214-225.	2.8	29
24	Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. <i>Annals of Oncology</i> , 2016, 27, 1733-1739.	1.2	28
25	Sexual Activity and Function in Patients With Gynecological Malignancies After Completed Treatment. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1134-1141.	2.5	25
26	Interaction of ER α and NRF2 Impacts Survival in Ovarian Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 112.	4.1	25
27	M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis. <i>Cells</i> , 2020, 9, 1224.	4.1	24
28	Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions. <i>Supportive Care in Cancer</i> , 2016, 24, 419-428.	2.2	20
29	Loss of <i>BRCA1</i> promotor hypermethylation in recurrent high-grade ovarian cancer. <i>Oncotarget</i> , 2017, 8, 83063-83074.	1.8	20
30	Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2862.	4.1	19
31	Podoplanin increases migration and angiogenesis in malignant glioma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 8663-70.	0.5	19
32	Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT). <i>Journal of Ovarian Research</i> , 2013, 6, 48.	3.0	18
33	Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1692-1698.	2.5	18
34	VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients. <i>Oncotarget</i> , 2017, 8, 43218-43227.	1.8	18
35	Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 211.	2.8	16
36	Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 00 <i>Journal of Gynecological Cancer</i> , 2021, 31, 1075-1079.	2.5	16

#	ARTICLE	IF	CITATIONS
37	Î2-arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation. <i>Frontiers in Endocrinology</i> , 2020, 11, 554733.	3.5	15
38	PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 569-577.	2.5	15
39	Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer. <i>Cancers</i> , 2021, 13, 3343.	3.7	14
40	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. <i>British Journal of Cancer</i> , 2018, 119, 330-338.	6.4	13
41	The G-Protein-Coupled Estrogen Receptor (GPER) Regulates Trimethylation of Histone H3 at Lysine 4 and Represses Migration and Proliferation of Ovarian Cancer Cells In Vitro. <i>Cells</i> , 2021, 10, 619.	4.1	13
42	Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival. <i>Histopathology</i> , 2018, 73, 1002-1012.	2.9	12
43	<p>Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7673-7684.	1.9	12
44	Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients. <i>Oncotarget</i> , 2018, 9, 982-994.	1.8	12
45	NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 1331-1345.	1.7	11
46	G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 564002.	3.5	11
47	Galectin-8 and -9 as prognostic factors for cervical cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1211-1220.	1.7	11
48	A Pilot Study of Gene Expression-Based Categorization of Pancreas Transplant Biopsies. <i>Transplantation</i> , 2009, 87, 222-226.	1.0	10
49	Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. <i>Gynecologic Oncology</i> , 2022, 165, 40-48.	1.4	10
50	Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. <i>Oncology Letters</i> , 2017, 14, 3302-3308.	1.8	9
51	Peri-operative oral immunonutrition in malnourished ovarian cancer patients assessed by the nutritional risk screening. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 1533-1538.	1.7	9
52	Participation of elderly gynecological cancer patients in clinical trials. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 797-804.	1.7	9
53	Cytoplasmic VDR expression as an independent risk factor for ovarian cancer. <i>Histochemistry and Cell Biology</i> , 2020, 154, 421-429.	1.7	9
54	Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gynecologic center in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 713-718.	1.7	9

#	ARTICLE	IF	CITATIONS
55	Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study. <i>Supportive Care in Cancer</i> , 2015, 23, 117-123.	2.2	8
56	EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2519-2527.	2.5	8
57	Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1923-1932.	2.5	8
58	H3K4me3 Is a Potential Mediator for Antiproliferative Effects of Calcitriol (1 α ,25(OH)2D3) in Ovarian Cancer Biology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2151.	4.1	8
59	Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs). <i>Breast Cancer Research</i> , 2021, 23, 45.	5.0	7
60	Trace Amine-Associated Receptor 1 (TAAR1) Is a Positive Prognosticator for Epithelial Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8479.	4.1	7
61	Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1067-1072.	1.0	6
62	Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 295.	4.1	6
63	Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer. <i>Histochemistry and Cell Biology</i> , 2020, 154, 189-195.	1.7	6
64	Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance Development. <i>Cancers</i> , 2021, 13, 3801.	3.7	6
65	Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6068-6068.	1.6	6
66	Platelet-Derived Growth Factor Receptor Beta Serum Concentrations during First-Line Therapy in Ovarian Cancer. <i>Oncology</i> , 2013, 85, 69-77.	1.9	5
67	Adjuvant therapy in node-positive vulvar cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 839-844.	2.4	5
68	Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e37.	2.2	5
69	AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin. <i>Scientific Reports</i> , 2022, 12, 1862.	3.3	5
70	A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 662-668.	2.5	5
71	Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2559-2574.	2.5	4
72	Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer. <i>Translational Oncology</i> , 2021, 14, 100910.	3.7	4

#	ARTICLE	IF	CITATIONS
73	Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway. <i>Biomedicines</i> , 2021, 9, 706.	3.2	4
74	The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1541-1549.	1.7	4
75	The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine. <i>Cells</i> , 2021, 10, 2337.	4.1	4
76	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. <i>Anticancer Research</i> , 2016, 36, 1015-22.	1.1	4
77	Malignant Transformation of a Serous Borderline Tumor and Early Metastasis of Associated Low-Grade Serous Carcinoma Detected on Screening Mammography. <i>Journal of Clinical Oncology</i> , 2011, 29, e763-e765.	1.6	3
78	Actin Beta-Like 2 as a New Mediator of Proliferation and Migration in Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 713026.	2.8	3
79	Inhibition of Wnt signaling as therapeutic option in platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e17050-e17050.	1.6	3
80	Subcellular Distribution of Thyroid Hormone Receptor Beta in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2698.	4.1	3
81	No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas. <i>Journal of Neurology</i> , 2018, 265, 431-432.	3.6	2
82	Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus. <i>Journal of Ovarian Research</i> , 2021, 14, 89.	3.0	2
83	Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies. <i>Cancers</i> , 2021, 13, 3349.	3.7	2
84	The role of resveratrol, Sirtuin1 and RXR's as prognostic markers in ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 1559-1572.	1.7	2
85	Lost in effusion. <i>Lancet, The</i> , 2012, 380, 620.	13.7	1
86	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5071-5071.	1.6	1
87	The risk of contralateral non sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16600-e16600.	1.6	1
88	A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FR's)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5618-TPS5618.	1.6	1
89	Cyclic transcutaneous bleeding after repeated cesarean section deliveries. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 202.	1.3	0
90	Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT).. <i>Journal of Clinical Oncology</i> , 2013, 31, e16535-e16535.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Surgical staging and its prognostic impact on patients with borderline ovarian tumors (BOT): A subanalysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.. Journal of Clinical Oncology, 2014, 32, 5562-5562.	1.6	0
92	Prognostic and predictive value of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.. Journal of Clinical Oncology, 2015, 33, 5552-5552.	1.6	0
93	Lymphonodektomie beim Vulvakarzinom. , 2017, , 167-176.		0
94	Participation of elderly gynecological cancer patients in clinical trials.. Journal of Clinical Oncology, 2017, 35, e21520-e21520.	1.6	0
95	The Value of Anti-angiogenics in Ovarian Cancer Therapy. , 2019, , 529-543.		0